Eli Lily Recruiting for Phase 2 Trial to Test LY3154207 for Parkinson’s Dementia

Eli Lily Recruiting for Phase 2 Trial to Test LY3154207 for Parkinson’s Dementia

Eli Lilly is recruiting patients for its Phase 2 clinical trial evaluating LY3154207 as a potential treatment for Parkinson’s disease dementia (PDD).

Parkinson’s disease destroys the nerve cells that make dopamine, a key player in nerve cell communication and involved in movement control, cognition, memory, learning, attention, and sleep.

Parkinson’s main affected brain area is the substantia nigra, which controls movement, but as the disease progresses and spreads in the brain, it can affect the areas responsible for mental functions, memory, and judgment.

About 50 percent of Parkinson’s patients will experience some form of cognitive impairment, which is diagnosed as Parkinson’s disease dementia when it affects more than one area of cognition and is severe enough to impair social or work functioning.

Symptoms of PDD can include attention difficulties, forgetfulness, and slow thought processes. This can make communication difficult, as remembering words and names and following conversations can be challenging.

Eli Lilly is developing LY3154207, an orally administered enhancer of dopamine receptor D1 — a type of dopamine receptor involved in cognition — for the treatment of PDD.

Previous preclinical studies have shown that enhancing dopamine receptor D1 can improve cognitive function, including attention.

In March 2017, a Phase 1 study (NCT02562768) evaluating LY3154207’s safety, tolerability, and how the body processes the therapy, was completed in healthy volunteers and Parkinson’s patients.

Now, a randomized placebo-controlled Phase 2 study called PRESENCE (NCT03305809) will evaluate the safety and effectiveness of three doses of LY3154207 in patients with mild-to-moderate Parkinson’s disease dementia.

Ely Lilly seeks to enroll 340 individuals, 46-85 years old, in centers from four countries: U.S., Canada, China, and Puerto Rico. Participants must have Parkinson’s disease with at least two years of symptoms, have PDD with a decline in cognitive function leading to functional impairment, have no history of a stroke in the past six months, and no signs/diagnosis of psychotic diseases.

Participants will be chosen randomly to receive daily either one of the three doses of LY3154207, or a placebo, for 12 weeks.

The study’s main goal is improvement in the ability to sustain concentration for a period of time without error — assessed through the Continuity of Attention (CoA) Composite Score of the Cognitive Drug Research Computerized Cognition Battery (CDR-CCB).

Secondary goals include improvements in cognitive function and attention, daytime sleepiness, dementia-related behavioral symptoms, activities of daily life, and motor function.

The PRESENCE study is estimated to conclude by July 2019.

4 comments

  1. Reijo Kivilehto says:

    There does not exist many studies to map the root cause of Parkinson Disease. Or are there?

    Wouldn’t it be easier to develop medicine or preventive measures (including medicine) after recognizing the root cause(s)?

    Pronably I have missed some information.

  2. Susan Todd says:

    I am a 71 year old female who has had PD for 10yrs . I would like to have the opportunity to interview to be a participant in the study. I do meet your criteria. I have been a few studies previously.

    I want to do whatever I can to help the scientist find a cure for PDD.
    I fight this disease on a daily basis.
    Susan
    2392411861

    • HOW about using “BIG DATA” in finding the root cause(s) ? here has lately been discussion about Presidential Election (whether Cambridge Analytics can influence on crowds and that would control voting behavior).

      I believe big data would speed up the research of neurological diseases

  3. Barre Rorabaugh says:

    Please let me know how to sign up for the Eli Lily Phase 2 study. My wife has PD for 15 years. Four years ago she had DBS surgery which significantly improved her tremors and dysknesia. However, over the past year she is showing some signs of cognitive decline but they are minor at this point

Leave a Comment

Your email address will not be published. Required fields are marked *